blood clot in the brain (poor, wavy eyesight, slurred speech, extreme exhaustion within 20-30 minutes of clot onset); poor, wavy eyesight; slurred speech; extreme exhaustion within 20-30 minutes of clot onset; This spontaneous case was reported by a consumer and describes the occurrence of CEREBRAL THROMBOSIS (blood clot in the brain (poor, wavy eyesight, slurred speech, extreme exhaustion within 20-30 minutes of clot onset)), OCULAR DISCOMFORT (poor, wavy eyesight), DYSARTHRIA (slurred speech) and FATIGUE (extreme exhaustion within 20-30 minutes of clot onset) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No relevant medical history was reported.  The patient's past medical history included Cerebral thrombosis on 09-Apr-2021, Cerebral thrombosis on 26-Apr-2021, Cerebral thrombosis on 13-May-2021, Cerebral thrombosis on 19-May-2021, Cerebral thrombosis on 05-Jun-2021 and Cerebral thrombosis. Concomitant products included OMEPRAZOLE, SIMVASTATIN, LOSARTAN and ASPIRIN [ACETYLSALICYLIC ACID] for an unknown indication.    On 27-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 29-Mar-2021, the patient experienced CEREBRAL THROMBOSIS (blood clot in the brain (poor, wavy eyesight, slurred speech, extreme exhaustion within 20-30 minutes of clot onset)) (seriousness criteria hospitalization, disability, medically significant and life threatening), OCULAR DISCOMFORT (poor, wavy eyesight) (seriousness criteria hospitalization, disability and life threatening), DYSARTHRIA (slurred speech) (seriousness criteria hospitalization, disability and life threatening) and FATIGUE (extreme exhaustion within 20-30 minutes of clot onset) (seriousness criteria hospitalization, disability and life threatening). The patient was hospitalized from 29-Mar-2021 to 01-Apr-2021 due to CEREBRAL THROMBOSIS, DYSARTHRIA, FATIGUE and OCULAR DISCOMFORT. The patient was treated with CLOPIDOGREL BISULFATE (PLAVIX) for Thrombosis, at an unspecified dose and frequency and AMLODIPINE for Thrombosis, at a dose of 5 mg. At the time of the report, CEREBRAL THROMBOSIS (blood clot in the brain (poor, wavy eyesight, slurred speech, extreme exhaustion within 20-30 minutes of clot onset)), OCULAR DISCOMFORT (poor, wavy eyesight), DYSARTHRIA (slurred speech) and FATIGUE (extreme exhaustion within 20-30 minutes of clot onset) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ultrasound scan: unknown (Inconclusive) unknown.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       While admitted, the patient had "a bunch of tests done" and was started on clopidogrel and amlodipine. After discharge, the patient had an ultrasound of the arteries in his head and neck, the results of which were not provided.   The reporter stated that the patient had five known episodes (and one episode on an unknown date and time) that mimicked the events on 29March2021 except without the eyesight and speech problems. These occurred on 09April 021 around 1730, 26April 2021 around 1300, 13May2021 around 1600, 19May2021 around 0940 and 05June2021 around 0739.  Very limited information regarding these events has been provided at this time. Further information has been requested.; Sender's Comments: Very limited information regarding these events has been provided at this time. Further information has been requested.